Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Nivolumab & Hodgkin Lymphoma, Nivolumab is approved for classical Hodgkin lymphoma by both the FDA and EMA, initially in the relapsed/refractory setting (1, 2)
The clinical phase II trial, identified as NCT02181738 or CheckMate 205, demonstrated that with extended follow-up, responses to nivolumab were both frequent and long-lasting. Nivolumab appears to be linked with a favorable safety profile and offers long-term benefits for a wide range of patients dealing with relapsed or refractory [classical Hodgkin lymphoma (cH…